EC Number   |
Source Tissue |
Reference |
|---|
    1.14.14.14 | ovary |
ovarian aromatase activity is significantly decreased by treatments with estradiol or ethynylestradiol |
744150 |
| 1.14.14.14 | placenta |
- |
724158, 724244, 725325, 725327, 725329, 725832, 726036, 744512, 764239, 765220, 765542 |
| 1.14.14.14 | placenta |
during the early phases of embryonic development, placental aromatase activity is comparable to that in maternal ovaries, but declines significantly at progressive stages of gestation |
745021 |
| 1.14.14.14 | SAOS-2 cell |
- |
745452 |
| 1.14.14.14 | T-98G cell |
cell line expresses aromatase mRNA and shows a cytoplasmic pattern of aromatase immunoreactivity. In addition, the cell line expresses estrogen receptor alpha |
726047 |
| 1.14.14.14 | testis |
high transcript abundance in the ovary and female brain, followed by the testis and male brain, and female liver and muscle |
745022 |
| 1.14.14.14 | testis |
immunoreactivities against aromatase and estradiol-17beta are detected in the cells along the inside of the acinar wall of the testis |
724783 |
| 1.14.14.14 | U-373MG cell |
cell line expresses aromatase mRNA and shows a cytoplasmic pattern of aromatase immunoreactivity. In addition, the cell line expresses estrogen receptor alpha |
726047 |
| 1.14.14.14 | ZR-75-1 cell |
- |
765383 |
